Literature DB >> 7439807

Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology.

R W Chapman, B A Arborgh, J M Rhodes, J A Summerfield, R Dick, P J Scheuer, S Sherlock.   

Abstract

Twenty-nine patients with primary sclerosing cholangitis were reviewed. Males predominated (2:1). Seventy-six per cent presented with cholestasis and cholangitis, 17% with cirrhosis and portal hypertension, and 7% were asymptomatic, presenting with a raised serum alkaline phosphatase. The serum immunoglobulin IgM concentration was raised in 45% of the patients, but no patient had serum mitochondrial antibody present. Seventy-two per cent had ulcerative proctocolitis. There was no relationship between either duration or severity of ulcerative proctocolitis and the development of primary sclerosing cholangitis. Four patients were not benefited by colectomy. None of the patients ahd Crohn's disease. The prognosis was variable. Corticosteriods and azathioprine were ineffective. Eleven patients (38%) had died with a mean survival time of seven years from diagnosis. Three patients with ulcerative proctocolitis developed bile duct carcinoma. The cholangiograms and liver biopsies were reported without reference to clinical information together with 41 patients with other biliary diseases. Cholangiography was diagnostic in 18/22 (82%). Hepatic histology was diagnostic in 8/22 (36%). Ten showed features of large bile duct disease and three were misdiagnosed as primary biliary cirrhosis. Reduced numbers of bile ducts, ductular proliferation, portal inflammation, and substantial copper deposition, in combination with piecemeal necrosis, are commonly seen in primary sclerosing cholangitis and indicate the need for cholangiography.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7439807      PMCID: PMC1419383          DOI: 10.1136/gut.21.10.870

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  The presentation and diagnosis of 100 patients with primary biliary cirrhosis.

Authors:  S Sherlock; P J Scheuer
Journal:  N Engl J Med       Date:  1973-09-27       Impact factor: 91.245

2.  Endoscopic retrograde cholangiographic evaluation of sclerosing cholangitis.

Authors:  H B Lefton; E I Winkelman
Journal:  Cleve Clin Q       Date:  1974

Review 3.  Immunological aspects of viral hepatitis.

Authors:  E J Holborow
Journal:  Br Med Bull       Date:  1972-05       Impact factor: 4.291

4.  Immunoglobulins in chronic liver disease.

Authors:  T Feizi
Journal:  Gut       Date:  1968-04       Impact factor: 23.059

5.  Retrograde cholangiography and sclerosing cholangitis.

Authors:  A A Abbruzzese
Journal:  Am J Dig Dis       Date:  1974-06

6.  Biliary tract carcinoma associated with ulcerative colitis.

Authors:  J K Ritchie; R N Allan; J Macartney; H Thompson; P R Hawley; W T Cooke
Journal:  Q J Med       Date:  1974-04

7.  The roentgenologic appearance of sclerosing cholangitis.

Authors:  J Krieger; W B Seaman; M R Porter
Journal:  Radiology       Date:  1970-05       Impact factor: 11.105

8.  Primary sclerosing cholangitis. A study of forty-two cases.

Authors:  K W Warren; S Athanassiades; J I Monge
Journal:  Am J Surg       Date:  1966-01       Impact factor: 2.565

9.  Primary sclerosing cholangitis, the biliary tree, and ulcerative colitis.

Authors:  M E Thorpe; P J Scheuer; S Sherlock
Journal:  Gut       Date:  1967-10       Impact factor: 23.059

10.  Primary intrahepatic obliterating cholangitis: a possible variant of 'sclerosing cholangitis'.

Authors:  P S Bhathal; L W Powell
Journal:  Gut       Date:  1969-11       Impact factor: 23.059

View more
  145 in total

1.  Asymptomatic primary sclerosing cholangitis with marked hepatic fibrosis.

Authors:  H Kawai; Y Aoyagi; M Nomoto; H Takizawa; Y Suzuki; A Hama; T Suda; T Takahashi; H Asakura
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

Review 2.  Primary sclerosing cholangitis.

Authors:  S A Mitchell; R W Chapman
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

Review 3.  The management of primary sclerosing cholangitis.

Authors:  Roger W Chapman
Journal:  Curr Gastroenterol Rep       Date:  2003-02

4.  Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLA-DRB1*13 but not with tumour necrosis factor alpha -308 promoter polymorphism.

Authors:  P L Bittencourt; S A Palacios; E L R Cançado; F J Carrilho; G Porta; J Kalil; A C Goldberg
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

5.  Surgical aspects of sclerosing cholangitis. Results in 178 patients.

Authors:  F M Martin; R L Rossi; F W Nugent; F J Scholz; R L Jenkins; W D Lewis; M Gagner; E Foley; J W Braasch
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

Review 6.  Are the inflammatory bowel diseases autoimmune disorders?

Authors:  J Snook
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

7.  Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population.

Authors:  C Y Ponsioen; S M E Vrouenraets; W Prawirodirdjo; R Rajaram; E A J Rauws; C J J Mulder; J B Reitsma; S H Heisterkamp; G N J Tytgat
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

8.  Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab.

Authors:  Ileana Duca; Patricia Ramírez de la Piscina; Silvia Estrada; Rosario Calderón; Katerina Spicakova; Leire Urtasun; Carlos Marra-López; Salvador Zabaleta; Raquel Bengoa; María Asunción Marcaide; Francisco García-Campos
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

9.  Expression of laminin in benign and malignant sclerosing lesions of extrahepatic bile ducts.

Authors:  C Haglund; P J Roberts; S Nordling
Journal:  J Clin Pathol       Date:  1989-09       Impact factor: 3.411

Review 10.  Primary sclerosing cholangitis: diagnosis and treatment.

Authors:  Holger Lutz; Christian Trautwein; Jens W Tischendorf
Journal:  Dtsch Arztebl Int       Date:  2013-12-23       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.